Skip to main content
main-content

Breast cancer

12-10-2018 | Breast cancer | Highlight | Article

Editor's pick

Endocrine therapy impacts cardiovascular risk in women with breast cancer

Long-term use of adjuvant endocrine therapy by women with a history of nonmetastatic breast cancer can significantly alter their risk for some types of cardiovascular disease, a meta-analysis shows.

Source:

BMJ 2018; 363: k3845

11-10-2018 | Breast cancer | News | Article

News in brief

Postmenopausal weight loss linked to reduced breast cancer risk

Postmenopausal women who lose weight have a lower risk for breast cancer than those who maintain a stable weight, report researchers.

10-10-2018 | Oncology | News | Article

Short-term hospitalization, mortality risk varies by palliative chemotherapy regimen

Two independent studies of older patients receiving initial chemotherapy for metastatic breast cancer or non-small-cell lung cancer have found that the risk for hospitalization or death may be predicted by the cytotoxic regimen used.

Source:

Cancer 2018; doi:10.1002/cncr.31760
JAMA Network Open 2018; 1: e183023

09-10-2018 | Breast cancer | News | Article

Lurbinectedin activity shown in metastatic breast cancer

Lurbinectedin, a selective inhibitor of active transcription of protein-coding genes, has promising activity in patients with BRCA1/2-mutated metastatic breast cancer, phase II study data show.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.2018.78.6558

20-09-2018 | Oncology | Main feed | News

Early atezolizumab results point to potential role in metastatic TNBC care

Phase I trial findings suggest that patients with metastatic triple-negative breast cancer might benefit from treatment with the programmed cell death ligand 1 inhibitor atezolizumab.

Source:

JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.4224

18-09-2018 | Oncology | Main feed | News

approvalsWatch

Durvalumab, abemaciclib approvals announced by EMA

Click through to read more

image credits